East Hanover, NJ. October 7, 2019. With a grant from the Consortium of Multiple Sclerosis Centers, John DeLuca, PhD, Helen Genova, PhD, of [...]
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at [...]
Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS [...]
The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably [...]
Relationships between multiple sclerosis patients and their intimate partners were enhanced when the couple worked together to make [...]
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis [...]
Study by MS research team links deficits in social cognition with fatigue, depressive symptomatology, and anxiety Date: August 29, [...]
Researchers say genetic makeup is a factor, but so are smoking, obesity, vitamin D, and viral infections. A combination of genetic and [...]